Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  pegylated liposomal doxorubicin hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 62 for your search:
Start Over
A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging
Phase: Phase IV
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: LITE Randomized Pilot Study, NCT00531973
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 19 and over
Sponsor: NCI
Protocol IDs: NCI-2014-00629, GOG-0281, U10CA180868, U10CA027469, NCT02101788
Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MITO-8, 2008-001755-22, NCT00657878
Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FEDEGYN 02 / 0410-CHIPOR, 2010-023035-42, NCT01376752
INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ET-D-009-10, NCT01379989
Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: ACTG A5263, 1U01AI068636, U01CA121947, NCT01435018
Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MITO-16 -MANGO-OV2b, 2012-004362-17, ENGOT-ov 17, NCT01802749
Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AGO-OVAR 2.21 / ENGOT ov-18, NCT01837251
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR100983, ET743OVC3006, 2012-004808-34, NCT01846611
Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia:
Phase: Phase III
Type: Treatment
Status: Active
Age: 14 to 60
Sponsor: Pharmaceutical / Industry
Protocol IDs: ChangzhouJP, NCT02070523
CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: CMA-MM, NCT02336386
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PM1183-C-004-14, NCT02421588
R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 60 to 80
Sponsor: Other
Protocol IDs: 308-2015-005, NCT02428751
Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Status: Approved-not yet active
Age: Not specified
Sponsor: NCI
Protocol IDs: NCI-2015-00606, NRG-GY004, U10CA180868, NCT02446600
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0711003269, NCT00785798
Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LAPADO-Study, 2007-000924-42, NCT01172223
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MM08-141, NCT01177683
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 201102043, NCI-2011-00224, NCT01246063
Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PO-MM-PI-0049, PDD-2011, NCT01541332
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: APR-407, NCT02098343
Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-17814, NCT02186834
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: X16041, IISR-2013-M100118, NCT02206425
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PembroPlus, NCT02331251
A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2014-001, NCT02431559
Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000065903, UTHSC-MS-96205, NCI-V97-1356, NCT00003135
Start Over